• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HCV NS5B 聚合酶的结构和调节元件 - β-环和 C 末端尾巴 - 是变构拇指位点 II 抑制剂活性所必需的。

Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.

机构信息

Gilead Sciences Inc., Foster City, California, United States of America.

出版信息

PLoS One. 2014 Jan 9;9(1):e84808. doi: 10.1371/journal.pone.0084808. eCollection 2014.

DOI:10.1371/journal.pone.0084808
PMID:24416288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3886995/
Abstract

Elucidation of the mechanism of action of the HCV NS5B polymerase thumb site II inhibitors has presented a challenge. Current opinion holds that these allosteric inhibitors stabilize the closed, inactive enzyme conformation, but how this inhibition is accomplished mechanistically is not well understood. Here, using a panel of NS5B proteins with mutations in key regulatory motifs of NS5B--the C-terminal tail and β-loop--in conjunction with a diverse set of NS5B allosteric inhibitors, we show that thumb site II inhibitors possess a distinct mechanism of action. A combination of enzyme activity studies and direct binding assays reveals that these inhibitors require both regulatory elements to maintain the polymerase inhibitory activity. Removal of either element has little impact on the binding affinity of thumb site II inhibitors, but significantly reduces their potency. NS5B in complex with a thumb site II inhibitor displays a characteristic melting profile that suggests stabilization not only of the thumb domain but also the whole polymerase. Successive truncations of the C-terminal tail and/or removal of the β-loop lead to progressive destabilization of the protein. Furthermore, the thermal unfolding transitions characteristic for thumb site II inhibitor-NS5B complex are absent in the inhibitor-bound constructs in which interactions between C-terminal tail and β-loop are abolished, pointing to the pivotal role of both regulatory elements in communication between domains. Taken together, a comprehensive picture of inhibition by compounds binding to thumb site II emerges: inhibitor binding provides stabilization of the entire polymerase in an inactive, closed conformation, propagated via coupled interactions between the C-terminal tail and β-loop.

摘要

阐明 HCV NS5B 聚合酶拇指结构域 II 抑制剂的作用机制一直是一个挑战。目前的观点认为,这些变构抑制剂稳定了闭合的、无活性的酶构象,但这种抑制作用的机制尚不清楚。在这里,我们使用一组带有 NS5B 关键调节模体(C 端尾巴和β环)突变的 NS5B 蛋白,结合一组不同的 NS5B 变构抑制剂,表明拇指结构域 II 抑制剂具有独特的作用机制。酶活性研究和直接结合测定的组合表明,这些抑制剂需要两个调节元件来维持聚合酶抑制活性。去除任何一个元件对拇指结构域 II 抑制剂的结合亲和力几乎没有影响,但显著降低了它们的效力。与拇指结构域 II 抑制剂结合的 NS5B 显示出特征性的熔融曲线,这表明不仅稳定了拇指结构域,而且稳定了整个聚合酶。C 端尾巴和/或β环的连续截短导致蛋白的逐渐不稳定。此外,在结合抑制剂的结构中,没有特征性的拇指结构域 II 抑制剂-NS5B 复合物的热变性转变,这表明 C 端尾巴和β环之间的相互作用在结构域之间的通讯中起着关键作用。综上所述,化合物结合到拇指结构域 II 的抑制作用的综合图景出现了:抑制剂结合提供了整个聚合酶在无活性的闭合构象中的稳定性,通过 C 端尾巴和β环之间的偶联相互作用来传递。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/c39d6920e88b/pone.0084808.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/c8227121e84a/pone.0084808.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/40d999a22fa9/pone.0084808.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/d3c7862ddc5a/pone.0084808.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/98a3cf1fa2b9/pone.0084808.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/ee690c8604c7/pone.0084808.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/c39d6920e88b/pone.0084808.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/c8227121e84a/pone.0084808.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/40d999a22fa9/pone.0084808.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/d3c7862ddc5a/pone.0084808.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/98a3cf1fa2b9/pone.0084808.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/ee690c8604c7/pone.0084808.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6efe/3886995/c39d6920e88b/pone.0084808.g006.jpg

相似文献

1
Structural and regulatory elements of HCV NS5B polymerase--β-loop and C-terminal tail--are required for activity of allosteric thumb site II inhibitors.HCV NS5B 聚合酶的结构和调节元件 - β-环和 C 末端尾巴 - 是变构拇指位点 II 抑制剂活性所必需的。
PLoS One. 2014 Jan 9;9(1):e84808. doi: 10.1371/journal.pone.0084808. eCollection 2014.
2
NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.核磁共振揭示了NS5A蛋白的内在无序结构域2作为丙型肝炎病毒RNA聚合酶NS5B的变构调节剂。
J Biol Chem. 2017 Nov 3;292(44):18024-18043. doi: 10.1074/jbc.M117.813766. Epub 2017 Sep 14.
3
Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.丙型肝炎病毒2a型RNA依赖性RNA聚合酶的晶体结构揭示了两种构象,并提出了非核苷抑制剂的抑制机制。
J Biol Chem. 2005 May 6;280(18):18202-10. doi: 10.1074/jbc.M413410200. Epub 2005 Mar 2.
4
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.丙型肝炎病毒NS5B聚合酶一类非核苷抑制剂的结合位点表征及耐药性
J Biol Chem. 2005 Nov 25;280(47):39260-7. doi: 10.1074/jbc.M506407200. Epub 2005 Sep 27.
5
Ligand-induced changes in hepatitis C virus NS5B polymerase structure.配体诱导的丙型肝炎病毒 NS5B 聚合酶结构变化。
Antiviral Res. 2010 Nov;88(2):197-206. doi: 10.1016/j.antiviral.2010.08.014. Epub 2010 Sep 9.
6
Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors.将 3-D 定量构效关系与基于配体和基于结构的对准程序相结合,用于新型丙型肝炎病毒 NS5B 聚合酶抑制剂的计算机筛选。
J Chem Inf Model. 2010 Apr 26;50(4):662-76. doi: 10.1021/ci9004749.
7
Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.拇指抑制剂结合消除了丙型肝炎病毒 RNA 聚合酶中功能重要的动力学。
Proteins. 2013 Jan;81(1):40-52. doi: 10.1002/prot.24154. Epub 2012 Sep 15.
8
Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.丙型肝炎病毒非核苷类聚合酶抑制剂的慢结合抑制作用及耐药机制
J Biol Chem. 2009 Jun 5;284(23):15517-29. doi: 10.1074/jbc.M808889200. Epub 2009 Feb 26.
9
Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.与丙型肝炎病毒NS5B聚合酶结合的非核苷抑制剂揭示了一种新的抑制机制。
J Mol Biol. 2006 Aug 4;361(1):33-45. doi: 10.1016/j.jmb.2006.05.074. Epub 2006 Jun 16.
10
Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase.药效团假说与分子对接相结合以鉴定丙型肝炎病毒NS5B聚合酶的新型抑制剂。
Mol Divers. 2015 Aug;19(3):529-39. doi: 10.1007/s11030-015-9591-5. Epub 2015 Apr 11.

引用本文的文献

1
The Use of Intrinsic Disorder and Phosphorylation by Oncogenic Viral Proteins to Dysregulate the Host Cell Cycle Through Interaction with pRb.致癌病毒蛋白利用内在无序和磷酸化通过与pRb相互作用来失调宿主细胞周期。
Viruses. 2025 Jun 10;17(6):835. doi: 10.3390/v17060835.
2
Geometric Deep learning Prioritization and Validation of Cannabis Phytochemicals as Anti-HCV Non-nucleoside Direct-acting Inhibitors.几何深度学习:大麻植物化学物质作为抗丙型肝炎病毒非核苷类直接作用抑制剂的优先级排序与验证
Biomed Eng Comput Biol. 2024 Dec 12;15:11795972241306881. doi: 10.1177/11795972241306881. eCollection 2024.
3
The IQA Energy Partition in a Drug Design Setting: A Hepatitis C Virus RNA-Dependent RNA Polymerase (NS5B) Case Study.

本文引用的文献

1
New horizons in hepatitis C antiviral therapy with direct-acting antivirals.直接作用抗病毒药物在丙型肝炎抗病毒治疗中的新进展。
Hepatology. 2013 Jul;58(1):428-38. doi: 10.1002/hep.26371. Epub 2013 May 31.
2
Hepatitis C virus-specific directly acting antiviral drugs.丙型肝炎病毒特异性直接作用抗病毒药物。
Curr Top Microbiol Immunol. 2013;369:289-320. doi: 10.1007/978-3-642-27340-7_12.
3
Hepatitis C virus RNA replication.丙型肝炎病毒 RNA 复制。
药物设计环境中的IQA能量分配:丙型肝炎病毒RNA依赖性RNA聚合酶(NS5B)案例研究
Pharmaceuticals (Basel). 2022 Oct 8;15(10):1237. doi: 10.3390/ph15101237.
4
Targeting HCV polymerase: a structural and dynamic perspective into the mechanism of selective covalent inhibition.靶向丙型肝炎病毒聚合酶:对选择性共价抑制机制的结构与动力学见解
RSC Adv. 2018 Dec 18;8(73):42210-42222. doi: 10.1039/c8ra07346e. eCollection 2018 Dec 12.
5
Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells.基于吡唑啉酮的化合物作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进入宿主细胞的有效阻滞剂的设计与合成
J Mol Struct. 2021 Oct 5;1241:130665. doi: 10.1016/j.molstruc.2021.130665. Epub 2021 May 13.
6
Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents.新型抗丙型肝炎病毒药物N'-亚芳基-6-(苄氧基)-4-氧代-1,4-二氢喹啉-3-碳酰肼衍生物的设计、合成、分子模拟研究及生物学评价
Iran J Pharm Res. 2019 Fall;18(4):1790-1802. doi: 10.22037/ijpr.2019.112186.13586.
7
Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the approach.丙型肝炎病毒1、2和3基因型的基线达沙布韦耐药性以及通过该方法对NS5B-达沙布韦复合物的建模。
Infect Ecol Epidemiol. 2018 Oct 5;8(1):1528117. doi: 10.1080/20008686.2018.1528117. eCollection 2018.
8
NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.核磁共振揭示了NS5A蛋白的内在无序结构域2作为丙型肝炎病毒RNA聚合酶NS5B的变构调节剂。
J Biol Chem. 2017 Nov 3;292(44):18024-18043. doi: 10.1074/jbc.M117.813766. Epub 2017 Sep 14.
9
Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase.丙型肝炎病毒(HCV)聚合酶变构抑制剂的生物物理作用模式及选择性分析
Viruses. 2017 Jun 16;9(6):151. doi: 10.3390/v9060151.
10
Biochemical Effect of Resistance Mutations against Synergistic Inhibitors of RSV RNA Polymerase.呼吸道合胞病毒RNA聚合酶协同抑制剂抗性突变的生化效应
PLoS One. 2016 May 10;11(5):e0154097. doi: 10.1371/journal.pone.0154097. eCollection 2016.
Curr Top Microbiol Immunol. 2013;369:167-98. doi: 10.1007/978-3-642-27340-7_7.
4
Hepatitis C virus proteins: from structure to function.丙型肝炎病毒蛋白:从结构到功能。
Curr Top Microbiol Immunol. 2013;369:113-42. doi: 10.1007/978-3-642-27340-7_5.
5
Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase.解析丙型肝炎病毒聚合酶非核苷抑制剂的相互作用机制和特性。
Antiviral Res. 2013 Mar;97(3):356-68. doi: 10.1016/j.antiviral.2012.12.027. Epub 2013 Jan 7.
6
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.GS-9669 的临床前特征:一种丙型肝炎病毒 NS5B 聚合酶拇指位点 II 抑制剂。
Antimicrob Agents Chemother. 2013 Feb;57(2):804-10. doi: 10.1128/AAC.02052-12. Epub 2012 Nov 26.
7
Differential scanning calorimetry as a tool for protein folding and stability.差示扫描量热法作为一种研究蛋白质折叠和稳定性的工具。
Arch Biochem Biophys. 2013 Mar;531(1-2):100-9. doi: 10.1016/j.abb.2012.09.008. Epub 2012 Sep 27.
8
Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.拇指抑制剂结合消除了丙型肝炎病毒 RNA 聚合酶中功能重要的动力学。
Proteins. 2013 Jan;81(1):40-52. doi: 10.1002/prot.24154. Epub 2012 Sep 15.
9
Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.新型丙型肝炎病毒 RNA 依赖性 RNA 聚合酶非核苷抑制剂 JTK-853 的临床前特征。
Antimicrob Agents Chemother. 2012 Aug;56(8):4250-6. doi: 10.1128/AAC.00312-12. Epub 2012 May 21.
10
Differential scanning fluorometry signatures as indicators of enzyme inhibitor mode of action: case study of glutathione S-transferase.差示扫描荧光法特征作为酶抑制剂作用模式的指示剂:谷胱甘肽 S-转移酶的案例研究。
PLoS One. 2012;7(4):e36219. doi: 10.1371/journal.pone.0036219. Epub 2012 Apr 30.